Pfizer Declares $0.43 Third-Quarter 2026 Dividend, Marking 351st Consecutive Quarterly Payout
核心洞察
Pfizer's board of directors declared a $0.43 per share cash dividend for the third quarter of 2026, payable on September 1, 2026.
The dividend will be paid to shareholders of record as of July 24, 2026, representing the 351st consecutive quarterly dividend.
Pfizer reaffirmed its commitment to maintaining and growing the dividend over the longer term as part of its capital allocation strategy.
Pfizer Inc. (NYSE: PFE) announced on June 24, 2026, that its board of directors has declared a third-quarter 2026 cash dividend of $0.43 per share on the company's common stock. The dividend is payable on September 1, 2026, to holders of record at the close of business on July 24, 2026.
The upcoming distribution marks the 351st consecutive quarterly dividend paid by Pfizer, underscoring the pharmaceutical giant's long-standing track record of returning capital to shareholders.
Capital Allocation Strategy
Pfizer stated that it remains "committed to maintaining, and over the longer term, growing the dividend, as part of its capital allocation strategy." This commitment comes as the company continues to navigate the post-COVID landscape while investing in its pipeline of innovative medicines and vaccines.
The dividend declaration reflects the board's confidence in Pfizer's financial position and future cash flow generation, even as the company faces the uncertainties inherent in pharmaceutical research and development.
Forward-Looking Considerations
In its disclosure notice, Pfizer cautioned that forward-looking statements regarding its dividend commitment involve substantial risks and uncertainties. These include, among other factors, the ability to meet anticipated clinical endpoints, regulatory submission and approval timelines, manufacturing capabilities, competitive developments, and the impact of business development transactions.
The company noted that actual results could differ materially from those expressed or implied, citing risks detailed in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and subsequent filings with the U.S. Securities and Exchange Commission.
About Pfizer
Pfizer applies science and global resources to develop therapies that extend and significantly improve patients' lives, spanning innovative medicines and vaccines. The company collaborates with healthcare providers, governments, and local communities to support and expand access to reliable, affordable healthcare worldwide.